California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
HAMPTON, N.J., March 03, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:00 a.m. EST in Boston.
The live webcast of the presentation will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be archived for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact: Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
